Your browser doesn't support javascript.
loading
Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma.
Jusakul, Apinya; Cutcutache, Ioana; Yong, Chern Han; Lim, Jing Quan; Huang, Mi Ni; Padmanabhan, Nisha; Nellore, Vishwa; Kongpetch, Sarinya; Ng, Alvin Wei Tian; Ng, Ley Moy; Choo, Su Pin; Myint, Swe Swe; Thanan, Raynoo; Nagarajan, Sanjanaa; Lim, Weng Khong; Ng, Cedric Chuan Young; Boot, Arnoud; Liu, Mo; Ong, Choon Kiat; Rajasegaran, Vikneswari; Lie, Stefanus; Lim, Alvin Soon Tiong; Lim, Tse Hui; Tan, Jing; Loh, Jia Liang; McPherson, John R; Khuntikeo, Narong; Bhudhisawasdi, Vajaraphongsa; Yongvanit, Puangrat; Wongkham, Sopit; Totoki, Yasushi; Nakamura, Hiromi; Arai, Yasuhito; Yamasaki, Satoshi; Chow, Pierce Kah-Hoe; Chung, Alexander Yaw Fui; Ooi, London Lucien Peng Jin; Lim, Kiat Hon; Dima, Simona; Duda, Dan G; Popescu, Irinel; Broet, Philippe; Hsieh, Sen-Yung; Yu, Ming-Chin; Scarpa, Aldo; Lai, Jiaming; Luo, Di-Xian; Carvalho, André Lopes; Vettore, André Luiz; Rhee, Hyungjin.
Afiliação
  • Jusakul A; Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore.
  • Cutcutache I; Laboratory of Cancer Epigenome, Division of Medical Science, National Cancer Centre Singapore, Singapore.
  • Yong CH; The Centre for Research and Development of Medical Diagnostic Laboratories and Department of Clinical Immunology and Transfusion Sciences, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen, Thailand.
  • Lim JQ; Centre for Computational Biology, Duke-NUS Medical School, Singapore.
  • Huang MN; Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore.
  • Padmanabhan N; Centre for Computational Biology, Duke-NUS Medical School, Singapore.
  • Nellore V; Laboratory of Cancer Epigenome, Division of Medical Science, National Cancer Centre Singapore, Singapore.
  • Kongpetch S; Lymphoma Genomic Translational Research Laboratory, National Cancer Centre Singapore, Division of Medical Oncology, Singapore.
  • Ng AWT; Centre for Computational Biology, Duke-NUS Medical School, Singapore.
  • Ng LM; Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore.
  • Choo SP; Department of Biostatistics and Bioinformatics, Center for Genomic and Computational Biology, Duke University, Durham, North Carolina.
  • Myint SS; Laboratory of Cancer Epigenome, Division of Medical Science, National Cancer Centre Singapore, Singapore.
  • Thanan R; Cholangiocarcinoma Screening and Care Program and Liver Fluke and Cholangiocarcinoma Research Centre, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
  • Nagarajan S; Department of Pharmacology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
  • Lim WK; NUS Graduate School for Integrative Sciences and Engineering, National University of Singapore, Singapore.
  • Ng CCY; Cancer Science Institute of Singapore, National University of Singapore, Singapore.
  • Boot A; Division of Medical Oncology, National Cancer Centre Singapore, Singapore.
  • Liu M; Laboratory of Cancer Epigenome, Division of Medical Science, National Cancer Centre Singapore, Singapore.
  • Ong CK; Department of Biochemistry, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
  • Rajasegaran V; Laboratory of Cancer Epigenome, Division of Medical Science, National Cancer Centre Singapore, Singapore.
  • Lie S; Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore.
  • Lim AST; Laboratory of Cancer Epigenome, Division of Medical Science, National Cancer Centre Singapore, Singapore.
  • Lim TH; Laboratory of Cancer Epigenome, Division of Medical Science, National Cancer Centre Singapore, Singapore.
  • Tan J; Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore.
  • Loh JL; Centre for Computational Biology, Duke-NUS Medical School, Singapore.
  • McPherson JR; Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore.
  • Khuntikeo N; Centre for Computational Biology, Duke-NUS Medical School, Singapore.
  • Bhudhisawasdi V; Lymphoma Genomic Translational Research Laboratory, National Cancer Centre Singapore, Division of Medical Oncology, Singapore.
  • Yongvanit P; Laboratory of Cancer Epigenome, Division of Medical Science, National Cancer Centre Singapore, Singapore.
  • Wongkham S; Laboratory of Cancer Epigenome, Division of Medical Science, National Cancer Centre Singapore, Singapore.
  • Totoki Y; Division of Radiation Oncology, National Cancer Centre Singapore, Singapore.
  • Nakamura H; Cytogenetics Laboratory, Department of Molecular Pathology, Singapore General Hospital, Singapore.
  • Arai Y; Cytogenetics Laboratory, Department of Molecular Pathology, Singapore General Hospital, Singapore.
  • Yamasaki S; Laboratory of Cancer Epigenome, Division of Medical Science, National Cancer Centre Singapore, Singapore.
  • Chow PK; Laboratory of Cancer Epigenome, Division of Medical Science, National Cancer Centre Singapore, Singapore.
  • Chung AYF; Centre for Computational Biology, Duke-NUS Medical School, Singapore.
  • Ooi LLPJ; Cholangiocarcinoma Screening and Care Program and Liver Fluke and Cholangiocarcinoma Research Centre, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
  • Lim KH; Department of Surgery, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
  • Dima S; Department of Surgery, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
  • Duda DG; Cholangiocarcinoma Screening and Care Program and Liver Fluke and Cholangiocarcinoma Research Centre, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
  • Popescu I; Department of Biochemistry, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
  • Broet P; Division of Cancer Genomics, National Cancer Center Research Institute, Tokyo, Japan.
  • Hsieh SY; Division of Cancer Genomics, National Cancer Center Research Institute, Tokyo, Japan.
  • Yu MC; Division of Cancer Genomics, National Cancer Center Research Institute, Tokyo, Japan.
  • Scarpa A; Laboratory of Molecular Medicine, Human Genome Center, The Institute of Medical Science, The University of Tokyo, Japan.
  • Lai J; Division of Surgical Oncology, National Cancer Center Singapore and Office of Clinical Sciences, Duke-NUS Medical School, Singapore.
  • Luo DX; Department of Hepatopancreatobiliary/Transplant Surgery, Singapore General Hospital, Singapore.
  • Carvalho AL; Department of Hepatopancreatobiliary/Transplant Surgery, Singapore General Hospital, Singapore.
  • Vettore AL; Department of Anatomical Pathology, Singapore General Hospital, Singapore.
  • Rhee H; Center of Digestive Diseases and Liver Transplantation, Fundeni Clinical Institute, Bucharest, Romania.
Cancer Discov ; 7(10): 1116-1135, 2017 10.
Article em En | MEDLINE | ID: mdl-28667006
Cholangiocarcinoma (CCA) is a hepatobiliary malignancy exhibiting high incidence in countries with endemic liver-fluke infection. We analyzed 489 CCAs from 10 countries, combining whole-genome (71 cases), targeted/exome, copy-number, gene expression, and DNA methylation information. Integrative clustering defined 4 CCA clusters-fluke-positive CCAs (clusters 1/2) are enriched in ERBB2 amplifications and TP53 mutations; conversely, fluke-negative CCAs (clusters 3/4) exhibit high copy-number alterations and PD-1/PD-L2 expression, or epigenetic mutations (IDH1/2, BAP1) and FGFR/PRKA-related gene rearrangements. Whole-genome analysis highlighted FGFR2 3' untranslated region deletion as a mechanism of FGFR2 upregulation. Integration of noncoding promoter mutations with protein-DNA binding profiles demonstrates pervasive modulation of H3K27me3-associated sites in CCA. Clusters 1 and 4 exhibit distinct DNA hypermethylation patterns targeting either CpG islands or shores-mutation signature and subclonality analysis suggests that these reflect different mutational pathways. Our results exemplify how genetics, epigenetics, and environmental carcinogens can interplay across different geographies to generate distinct molecular subtypes of cancer.Significance: Integrated whole-genome and epigenomic analysis of CCA on an international scale identifies new CCA driver genes, noncoding promoter mutations, and structural variants. CCA molecular landscapes differ radically by etiology, underscoring how distinct cancer subtypes in the same organ may arise through different extrinsic and intrinsic carcinogenic processes. Cancer Discov; 7(10); 1116-35. ©2017 AACR.This article is highlighted in the In This Issue feature, p. 1047.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias dos Ductos Biliares / Colangiocarcinoma / Estudo de Associação Genômica Ampla / Epigenômica Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias dos Ductos Biliares / Colangiocarcinoma / Estudo de Associação Genômica Ampla / Epigenômica Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article